Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer

Urologia Internationalis

Volumn 78, Issue 1, 2007, Pages 50-57

  Dolezal, J ^a   Vizda, J ^a   Odrazka, K ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Bone metastases; Bone pain; Prostate cancer; Samarium 153 EDTMP

Indexed keywords

LEXIDRONAM SAMARIUM SM 153;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; ANALGESICS, NON-NARCOTIC; BONE NEOPLASMS; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PAIN MEASUREMENT; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SAMARIUM; TREATMENT OUTCOME;

EID: 33845948289     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096935     Document Type: Article

References (29)

1. Ahonen A, Joensuu H, Hiltunen J, Hannelin M, Heikkila J, Jakobsson M, Jurvelin J, Kairemo K, Kumpulainen E, Kulmala J, et al: Samarium-153-EDTMP in bone metastases. J Nucl Biol Med 1994;38:123-127.
2. Alberts AS, Smit BJ, Louw WK, van Rensburg AJ, van Beek A, Kritzinger V, Nel JS: Dose-response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone. Radiother Oncol 1997;43:175-179.
3. Bouchet LG, Bolch WE, Murtu Goddu S, Howell RW, Rao DV: Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J Nucl Med 2000;41:682-687.
4. Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, Livingston RB, Gordon EE, Chapman CR, Appelbaum FR: Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993;34:1839-1844.
5. Crawford ED, Kozlowskij JM, Debruyne FM, Fair WR, Logothetis CJ, Balmer C, et al: The use of strontium-89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer. Urology 1994;44:481-485.
6. Eary JF, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M, Hartnett S, Fervency S, Addison SJ, Appelbaum F, Gordon EE: Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993;34:1031-1036.
7. Fuster D, Vidal-Sicart S, Alcover J, Martin F, Pons F: Usefulness of strontium-89 chloride in pain palliation of patients with prostate cancer and active bone metastases. Eur J Nucl Med 2003;30(suppl 2):S339.
8. Giammarile F, Mognetti T, Resche I: Bone pain palliation with strontium-89 in cancer patients with bone metastases. Q J Nucl Med 2001;45:78-83.
9. Giannakenas C, Kalofonos HP, Apostolopoulos DJ, Zarakovitis J, Kosmas C, Vassilakos PJ: Preliminary results of the use of 186 Re-HEDP for palliation of pain in patients with metastatic bone disease. Am J Clin Oncol 2000;23:83-88.
10. Han SH, De Klerk MH, Zonnenberg BA, Tan S, van Rijk PP: 186 Re-etidronate - efficacy of palliative radionuclide therapy for painful bone metastases. Q J Nucl Med 2001;45:84-90.
11. Heggie JCP: Radiation absorbed dose calculation for samarium-153 localized in bone. J Nucl Med 1991;32:840-844.
12. Ilchum KS, Chen D, Muggia F: A new look at radionuclides therapy in metastatic disease of bone. Anticancer Res 1988;8:681-684.
13. Kolesnikov-Gauthier H, Carpentier P, Depreux P, Vennin P, Caty A, Sulman C: Evaluation of toxicity and efficacy of 186 Rehydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. J Nucl Med 2000;41:1689-1694.
14. Kraeber-Bodere F, Campion L, Rousseau C, Bourdin S, Chatal JF, Resche I: Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med 2000;27:1487-1493.
15. Liepe K, Franke WG, Kropp J, Koch R, Runge R, Hlics R: Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases. Nuklearmedizin 2000;39:146-151.
16. Marcus CS, Steed S, Mlikotic A, Mishkin F, Pham HL, Javella T, Diestelhorst S, Minami C: Lack of effect of a biphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of 153 Sm-EDTMP. Clin Nucl Med 2002;27:427-430.
17. McEwan AJB: Use of radionuclides for the palliation of bone metastases. Semin Radiat Oncol 2000;10:103-114.
18. Modoni S, Varraso A, Urbano N, Valle G, Dicembrino F, Ritrovato G, Frusciante V: Palliative therapy with 153 Sm-EDTMP: two years of experience. Eur J Nucl Med 2003;30(suppl 2):S339.
19. Olea E, Pan Z, Parma EP, Pusuwan P, Riccabona G, Tian JH, Obaldo J, Padhy AK: Efficacy and toxicity of 153 Sm-EDTMP in the palliative treatment of painful bone metastases. World J Nucl Med 2002;1:21-27.
20. 153Sm-EDTMP in painful bone metastases therapy. Eur J Nucl Med 2003;30(suppl 2):S338.
21. 153Sm-ethylene diamine tetramethylene phosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997;33:1583-1591.
22. Saarto T, Janes R, Tenhunen M, Kouri M: Palliative radiotherapy in the treatment of skeletal metastases. Eur J Pain 2002;6:323-330.
23. Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, Kotler JA, Freeman LM, Olivier P: Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004;63:940-945.
24. Schoeneich G, Palmedo H, Dierke-Dzierzon C, Müller SC, Biersack HJ: Rhenium-186 HEDP: palliative radionuclide therapy of painful bone metastases. Scand J Urol Nephrol 1997;31:445-448.
25. Sciuto R, Tofani A, Festa A, Giannarelli D, Pasqualoni R, Maini CL: Short- and longterm effect of 186 Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med 2000;41:647-654.
26. Serafini AN: Systemic metabolic radiotherapy with samarium-153-EDTMP for the treatment of painful bone metastases. Q J Nucl Med 2001;45:91-99.
27. Singh A, Holmes RA, Farhangi M, Volkert WA, Williams A, Stringham LM, et al: Human pharmacokinetics of samarium-153-EDTMP in metastatic cancer. J Nucl Med 1989;30:1814-1818.
28. Tennvall J, Abrahamsson PA, Ahlgren G, Darte L, Flodgren P, Garkavij M, Strand SE: Palliative radiation with a radiolabeled diphosphonate (rhenium-186 etidronate in patients with hormone-refractory disseminated prostate carcinoma. Scand J Urol Nephrol 2000;34:188-193.
29. Wang RF, Zhang CL, Zhu SL, Zhu M: A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer. Med Princ Pract 2003;12:97-101.